Activity of aclidinium bromide, a new long-acting muscarinic antagonist: A phase i study

British Journal of Clinical Pharmacology

Volumn 69, Issue 5, 2010, Pages 458-464

  Schelfhout, Vanessa J ^a   Ferrer, Pau ^b   Jansat, Josep Maria ^c   Peris, Francesc ^c   Gil, Esther Garcia ^c   Pauwels, Romain A ^a   Joos, Guy F ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Centre Hospitalier de la Polynesie Francaise CHPF   (French Polynesia)

^c Sant Feliu de Llobregat ^*  (Spain)

Author keywords

Aclidinium; Anticholinergic; Bronchodilator; COPD; Long acting; Phase I

Indexed keywords

ACLIDINIUM BROMIDE; LONG ACTING DRUG; METHACHOLINE; MUSCARINIC RECEPTOR BLOCKING AGENT; PARACETAMOL; PLACEBO;

ADULT; AIRWAY CONDUCTANCE; AIRWAY RESISTANCE; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; LOW DRUG DOSE; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VIRUS MENINGITIS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TROPANES; YOUNG ADULT;

EID: 77950675030     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03622.x     Document Type: Article

References (23)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 2007 176 : 532 555.
2. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004 364 : 709 721.
3. Hogg JC, Chu F, Utokaparch S, Wood R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004 350 : 2645 2653.
4. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005 2 : 297 304.
5. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998 50 : 279 290.
6. Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther 2003 98 : 59 69.
7. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison to that in normal subjects. Chest 1989 96 : 984 987.
8. Nisar M, Earis JE, Pearson MG, Calverley PM. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992 146 : 555 559.
9. Gross NJ. Ipratropium bromide. N Engl J Med 1988 319 : 486 494.
10. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002 19 : 217 224.
11. Gross NJ. Tiotropium bromide. Chest 2004 126 : 1946 1953.
12. Engstrom CP, Persson LO, Larsson S, Ryden A, Sullivan M. Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax 1996 51 : 825 830.
13. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997 349 : 1498 1504.
14. Gavaldà A, Miralpeix M, Ramos I, Vilella D, Sentellas S, Alberti J, Ryder H, Beleta J. Aclidinium bromide, a novel muscarinic receptor combining long residence at M3 receptors and rapid plasma clearance. Eur Respir J 2007 30 (Suppl. 51 209S 210S.
15. Joos GF, Schelfhout VJ, Kanniess F, Ludwig-Sengpill A, Garcia Gil E, Montejo EM. Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a Phase II study. Eur Respir J 2007 30 (Suppl. 51 210S.
16. Almirall Internal Document. Four-week inhalation toxicity study in dogs. 1900 RCC 780388.
17. Almirall Internal Document. Four-week inhalation toxicity study in rats. 1900 RCC 780772.
18. Dubois AB, Botheho SY, Bedell GN, Marshall R, Comroe JH. A rapid plethysmographic method for measuring thoracic gas volume: a comparison with a nitrogen washout method for measuring functional residual capacity in normal subjects. J Clin Invest 1956 35 : 322 326.
19. Dubois AB, Botheho SY, Comroe JH. A new method for measuring airway resistance in man using a body plethysmograph: values in normal subjects and in patients with respiratory disease. J Clin Invest 1957 35 : 327 334.
20. Crapo R, Casaburi R, Coates A, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med 2000 161 : 309 329.
21. Houghton CM, Woodcock AA, Singh D. A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled ipratropium bromide in healthy subjects and patients with asthma. Br J Clin Pharmacol 2005 59 : 152 159.
22. Joos GF, Pauwels RA, Van der Straeten ME. The effect of nedocromil sodium on the bronchoconstrictor effect of neurokinin A in subjects with asthma. J Allergy Clin Immunol 1989 83 : 663 668.
23. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006 148 : 565 578.